GSK — GSK plc

GSK Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: Total sales increased by 8% year-over-year to GBP 8.5 billion.
• Core Operating Profit: Grew by 11%.
• Core Earnings Per Share (EPS): Increased by 14% to 55p.
• Cash Generation: Year-to-date cash generation reached GBP 6.3 billion.
• Dividend: A dividend of 16p was declared for the quarter.
• Operating Margin: Improved by 90 basis points to 33.9% year-to-date.
• R&D Investment: Increased by 10%, reflecting a focus on pipeline expansion.

2. Strategic Updates and Business Highlights

• Portfolio Strength: Continued growth in specialty medicines, particularly in oncology and HIV, with notable products like Benlysta (up 17%) and Jemperli (up 39%).
• FDA Approvals: Four FDA approvals secured this year, including BLENREP and anticipated approval for depemokimab by year-end.
• Sustainability Initiatives: Positive Phase III data for a low-carbon version of Ventolin, expected to launch in 2026.
• Investment in R&D: A commitment to invest $30 billion in R&D and advanced manufacturing in the U.S. over the next five years, including a new biologics factory.
• Business Development: Continued focus on expanding the pipeline through strategic acquisitions and partnerships.

3. Forward Guidance and Outlook

• Upgraded Guidance: Full-year sales expectations raised from 3%-5% to 6%-7%, with operating profit guidance increased to 9%-11% and EPS to 10%-12%.
• Long-Term Outlook: Confidence in achieving over GBP 40 billion in sales by 2031, with a focus on late-stage assets and pipeline growth.

4. Bad News, Challenges, or Points of Concern

• Medicare Redesign Impact: The impact of the IRA on GSK's revenue is expected to be at the lower end of the GBP 400 million to GBP 500 million range.
• Vaccines Performance: U.S. vaccine sales declined due to lower preseason inventory build and competitive pressures, with cautious near-term expectations.
• Supply Chain Challenges: Ongoing optimization efforts to scale up capacity for new medicines and vaccines.
• Competitive Pressures: Concerns about competition in the long-acting injectable market, particularly from Gilead's upcoming products.

5. Notable Q&A Insights

• Market Expectations: There is a EUR 6 billion revenue gap between market expectations for 2031 and GSK's target, primarily driven by underappreciated assets in oncology and respiratory.
• Shingrix Growth: Strong performance in Europe, but concerns about sustainability as the rollout matures. Future growth will depend on expanding into emerging markets.
• Depemokimab Launch Strategy: Focus on new biologic-naive patients, with high expectations from pulmonologists regarding its potential as a new standard of care.
• BLENREP Market Entry: The initial U.S. launch is expected to be gradual, with learnings from early European experiences informing strategy.
• Long-Acting Injectables: Q4M and Q6M products are positioned to capture significant market share, with patient preference for longer dosing intervals expected to drive adoption.

This summary encapsulates GSK's strong financial performance, strategic initiatives, and outlook while also addressing challenges and insights from the Q&A session.